Bio Special BioInvest
Pfizer Secures Up to $1.5 Billion From Blackstone to Advance Monthly GLP-1 Programme
Blackstone to provide Pfizer up to $1.5 billion through 2028 to support clinical program for GLP-1 receptor agonist Pfizer Inc. (NYSE: PFE) and Blackstone...
November 13, 2026 | News
Sanyou Bio Secures Nearly RMB 100 Million in Series C to Advance AI-Driven Drug R&D
Accelerating the Development of an AI-Driven Ecosystem for Innovative Drug R&D and Translation Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") rece...
November 11, 2026 | News
Merck Opens €300 Million Bioprocessing Hub in South Korea to Strengthen APAC Supply Chain
Merck’s largest life science investment in Asia-Pacific to date expands regional manufacturing capacity Integrated digital systems suppo...
October 30, 2026 | News
Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...
October 27, 2026 | News
Samsung Biologics Reports KRW 1.49 Trillion Q3 Revenue as Global Manufacturing Expansion Drives Growth
Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion Plant 5 ramp-up and U.S. manufacturing operations contribute to earn...
October 23, 2026 | Company results
ESTEVE CDMO Invests Over $80 Million to Expand Pharmaceutical Manufacturing Capabilities in China
After more than two decades in China, ESTEVE CDMO marks a new chapter in its commitment to the country and the region. With more than $...
October 23, 2026 | News
Continuity Biosciences Secures $9.6M Gates Foundation Grant to Advance Multi-Year HIV Prevention Implant
Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing to...
October 16, 2026 | News
12 Biotechs in Hong Kong's 18A Queue, and What Each Says It Will Spend the Money On
Every Hong Kong biotech applicant has to tell investors what it will do with the money it raises. On the evidence of the twelve 18A application proofs that...
October 07, 2026 | Analysis
CSL, Alentis Forge $1.55B Partnership to Advance Lixudebart for Kidney and Liver Diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared CSL and Alentis Therapeuti...
October 06, 2026 | News
Novartis Signs $7.8B RNA Therapeutics Deal With Abogen Biosciences
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other...
October 05, 2026 | News
Piramal Pharma Invests $5.3M to Expand Drug Substance Manufacturing in Canada
Piramal Pharma Solutions is investing over $5.3 million in its Aurora drug substance facility to upgrade site infrastructure. With its investment throug...
October 01, 2026 | Analysis
Novartis Inks Up to $900M Global Licensing Deal with BoomRay for Radioligand Therapy Asset
Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision onco...
September 23, 2026 | News
Novo Holdings Makes Strategic Investment in China’s Wound Care CDMO ForYou Medical
Novo Holdings, a leading global healthcare and life sciences investor, announced a strategic minority investment in Huizhou ForYou Medical Devices Co., Ltd...
September 14, 2026 | News
CordenPharma Invests €80M to Expand Sterile Injectable Manufacturing Capacity in Italy
CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional as...
September 11, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
